APVO (Aptevo Therapeutics, Inc.) יחס שווי שוק לשווי בספרים

Developing antibodies to combat solid and hematological tumors in collaboration with major partners minimizes costs for Aptevo Therapeutics (APVO). The current market-to-book ratio demonstrates volatility, where the value of 0.30 describes the current level. The technological breakthrough of the ADAPTIR platform in immunology contrasts with the company's acute liquidity shortage and growing debt burden.

Aptevo Therapeutics antibody development requires high intellectual capital costs, which is reflected in the company's relative capitalization metric on GURU.Markets. This indicator compares the issuer's market value with its book value. The ratio measures the market premium over net assets, determining the business's degree of maturity. A stable R&D composition minimizes operational risks, supporting fundamental value. Investors should avoid buying during sharp, impulsive spikes in this multiple.